Guangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital, Jinan University School of Medicine, Guangzhou, Guangdong 510632, P.R. China.
Department of Surgery, Guangzhou Red Cross Hospital, Jinan University School of Medicine, Guangzhou, Guangdong 510632, P.R. China.
Oncol Rep. 2019 Apr;41(4):2321-2328. doi: 10.3892/or.2019.6986. Epub 2019 Jan 28.
Ovarian cancer is the third most common type of gynecological tumor, in addition to being the most lethal. Cytoreductive surgery with chemotherapy is the standard treatment for ovarian cancer. It is necessary to identify novel chemotherapeutic methods, since current chemotherapy treatments are rarely effective for patients with advanced‑stage or recurrent ovarian cancer and may cause acute systemic toxicity. Icariin (ICA) is a prenylated flavonol glycoside derived from Herba Epimedii, a medicinal plant with a variety of pharmacological activities, including anticancer, antidiabetic and anti‑obesity effects. By analyzing cell viability, cell cycle and cell migration, the present study demonstrated that ICA inhibited the cell viability of the ovarian cancer cell line, SKOV3, and blocked cell cycle transition. ICA inhibited the expression of fuse binding protein 1 (FBP1), a critical regulator of proliferation and tumorigenesis through binding to the c‑Myc promoter, as well as β‑catenin, a key regulator in ovarian cancer initiation, metastasis, chemoresistance and recurrence. Furthermore, it was indicated that ICA inhibited the migration of SKOV3 cells. In accordance with our previous findings on high FBP1 expression in ovarian cancer, FBP1 was a potential target of ICA in ovarian cancer cells. Based on these results, the present study demonstrated that ICA may be a potential therapeutic agent for ovarian cancer treatment.
卵巢癌是除致死率最高外的第三大常见妇科肿瘤。细胞减灭术联合化疗是卵巢癌的标准治疗方法。因此，有必要寻找新的化疗方法，因为目前的化疗方法对晚期或复发性卵巢癌患者的疗效甚微，且可能引起急性全身毒性。淫羊藿苷（ICA）是一种来源于淫羊藿的苯丙素类黄酮糖苷，具有多种药理活性，包括抗癌、抗糖尿病和抗肥胖作用。通过分析细胞活力、细胞周期和细胞迁移，本研究表明 ICA 抑制卵巢癌细胞系 SKOV3 的细胞活力，并阻断细胞周期转换。ICA 通过与 c-Myc 启动子结合抑制增殖和肿瘤发生的关键调节因子融合结合蛋白 1（FBP1）的表达，以及卵巢癌起始、转移、化疗耐药和复发的关键调节因子 β-连环蛋白的表达。此外，研究表明 ICA 抑制 SKOV3 细胞的迁移。根据我们之前关于卵巢癌中 FBP1 高表达的发现，FBP1 可能是 ICA 在卵巢癌细胞中的潜在靶点。基于这些结果，本研究表明 ICA 可能是治疗卵巢癌的潜在治疗剂。
